此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

This Study Aims to Investigate the Efficacy of Photobiomodulation in the Treatment of Anti-MAG-induced Peripheral Neuropathy (LASER-MAG) (LASER-MAG)

2026年6月16日 更新者:Madame Rameau、Centre Hospitalier de Cornouaille

The Efficacy of Photobiomodulation in the Treatment of Anti-MAG-Induced Peripheral Neuropathy: LASER-MAG Study.

Patients treated in the hematology department of the Quimper/Cornouaille Hospital Center for IgM monoclonal gammopathy with anti-MAG and symptomatic peripheral neuropathy often reach a therapeutic impasse.

The treatment of neuropathic pain is complex, but recently a new non-pharmacological therapy, photobiomodulation, has shown evidence of efficacy and improved quality of life in the treatment of these peripheral neuropathies.

This new therapy uses low-intensity lasers; it is non-invasive, athermic, and has no reported side effects. The general principle is to expose tissues to visible light in the red and near-infrared spectrum to elicit a biological response.

The study aims to evaluate the efficacy and tolerability of photobiomodulation in this population of patients with anti-MAG neuropathy.

研究概览

地位

邀请报名

详细说明

The protocol includes 16 photobiomodulation sessions, with monitoring of disability scores (ONLS, R-ODS), pain scores (NPSI), and quality of life scores (QLQ C30, QLQ CIPN20).

研究类型

观察性的

注册 (估计的)

10

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Quimper、法国、29107
        • Centre Hospitalier de Cornouaille

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

取样方法

非概率样本

研究人群

patients treated at the Cornouaille Hospital in the hematology and neurology departments

描述

Inclusion Criteria:

  • IgM gammopathy with the presence of anti-MAG antibodies
  • symptomatic peripheral neuropathy
  • patient agreement

Exclusion Criteria:

  • Patients with a solid tumor located in areas exposed to PBM
  • Patients under legal guardianship (guardianship, conservatorship...)
  • cognitive disorders
  • Peripheral neuropathy of other aetiologies
  • Declining to participate

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
干预/治疗
patients
patients with anti-MAG neuropathy due to IgM monoclonal gammopathy
Each patient receives 16 sessions of PBM over 6 weeks using the ATP38 device. Both upper limbs are treated simultaneously for 12 minutes each. The lower limbs are also treated for 12 minutes each. Assessments of disability (ONLS, R-ODS), pain (NPSI), and quality of life (QLQ C30, QLQ CIPN20) are conducted weekly. Neurological and hematological consultations are conducted before and after PBM sessions.
其他名称:
  • 低激光治疗
  • PBM

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
To evaluate the efficacy of photobiomodulation in the symptomatic treatment of anti-MAG-induced peripheral neuropathies
大体时间:From enrollment to the end of treatment at 3 months
Rasch-built Overall Disability Scale (R-ODS) score (0 to 48 = worse outcome)
From enrollment to the end of treatment at 3 months
To evaluate the efficacy of photobiomodulation in the symptomatic treatment of anti-MAG-induced peripheral neuropathies
大体时间:From enrollment to the end of treatment at 3 months
Overall Neuropathy Limitations Scale (ONLS) score (0-12=worse outcome)
From enrollment to the end of treatment at 3 months

次要结果测量

结果测量
措施说明
大体时间
Improving the quality of life for patients with anti-MAG peripheral neuropathy
大体时间:From enrollment to the end of treatment at 3 months
EORTC QLQ-C30 score (28-112= worse outcome)
From enrollment to the end of treatment at 3 months
Improving the quality of life for patients with anti-MAG peripheral neuropathy
大体时间:From enrollment to the end of treatment at 3 months
EORTC QLQ-CIPN20 score (20 - 80 = worse outcome)
From enrollment to the end of treatment at 3 months
Stopping the progression of peripheral neuropathy
大体时间:From enrollment to the end of treatment at 3 months
Neuropathic Pain Symptom Inventory (NPSI) score. Each question is rated on a scale from 0 to 10, where 0 means no pain at all and 10 means the worst pain.
From enrollment to the end of treatment at 3 months
motor response of peripheral neuropathy
大体时间:From enrollment to the end of treatment at 3 months
10-meter walk test
From enrollment to the end of treatment at 3 months
toxicity of PBM
大体时间:From enrollment to the end of treatment at 3 months
Neuropathic Pain Symptom Inventory (NPSI) score. Each question is rated on a scale from 0 to 10, where 0 means no pain at all and 10 means the worst pain.
From enrollment to the end of treatment at 3 months
Efficacy of PBM in patient subgroups
大体时间:From enrollment to the end of treatment at 3 months
comparison of scores based on prior treatments received (anti-CD20 monoclonal antibody, polyvalent immunoglobulins, plasma exchange, corticosteroids)
From enrollment to the end of treatment at 3 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Le Clech LLC Lenaig, doctor、Centre Hospitalier de Cornouaille

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年6月9日

初级完成 (估计的)

2026年12月1日

研究完成 (估计的)

2026年12月1日

研究注册日期

首次提交

2026年6月10日

首先提交符合 QC 标准的

2026年6月16日

首次发布 (实际的)

2026年6月22日

研究记录更新

最后更新发布 (实际的)

2026年6月22日

上次提交的符合 QC 标准的更新

2026年6月16日

最后验证

2026年6月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

IPD 计划说明

anonymized patient details sharing scientific results after the study is completed

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅